CPHGF (Consun Pharmaceutical Group) Moat Score: 5/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPHGF Consun Pharmaceutical Group Ltd CPHGF
71 GF Score
Price $1.80
GF Value $1.11
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Consun Pharmaceutical Group Moat Score?

Consun Pharmaceutical Group CPHGF +9.09% 71 Moat Score is 5 as of Jul. 21, 2026. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,028 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 94.65% on this metric.

Consun Pharmaceutical Group has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Consun Pharmaceutical Group has Narrow Moat: Consun Pharmaceutical has a solid narrow moat due to its specialized pharmaceutical products and some customer loyalty. However, it operates in a competitive market with limited pricing power and regulatory challenges.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Consun Pharmaceutical Group might have Narrow Moat - Solid narrow moat.

Consun Pharmaceutical Group  (OTCPK:CPHGF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Consun Pharmaceutical Group Moat Score Related Terms

CPHGF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Moat Score falls into.


CPHGF
71GF Score
Consun Pharmaceutical Group Ltd CPHGF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Consun Pharmaceutical Group (CPHGF) has a Moat Score of 5 as of Jul. 21, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Consun Pharmaceutical Group ranks #55 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is Consun Pharmaceutical Group's Moat Score too high?
Consun Pharmaceutical Group's current Moat Score is 5. Based on the distribution chart, Consun Pharmaceutical Group ranks #55 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #55 out of 1028 companies for Moat Score. This places Consun Pharmaceutical Group in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Consun Pharmaceutical Group's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current Moat Score is 5. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Moat Score is 5 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11. GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.

Key valuation signals for CPHGF:

  • Moat Score: 5
  • GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Consun Pharmaceutical Group Business Description

Other Exchanges 01681:Hong KongC1P:Germany
Address 71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score

Get the complete analysis for CPHGF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$1.11
GF Value